Green Alpha Advisors LLC Invests $641,000 in Caribou Biosciences, Inc. $CRBU

Green Alpha Advisors LLC acquired a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 364,324 shares of the company’s stock, valued at approximately $641,000. Green Alpha Advisors LLC owned 0.37% of Caribou Biosciences as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of CRBU. AQR Capital Management LLC grew its position in Caribou Biosciences by 741.6% in the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after purchasing an additional 463,391 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Caribou Biosciences during the first quarter valued at approximately $61,000. Creative Planning bought a new stake in shares of Caribou Biosciences during the second quarter valued at approximately $25,000. XTX Topco Ltd acquired a new position in shares of Caribou Biosciences during the second quarter worth approximately $133,000. Finally, Jane Street Group LLC boosted its position in shares of Caribou Biosciences by 64.7% during the second quarter. Jane Street Group LLC now owns 483,610 shares of the company’s stock worth $609,000 after buying an additional 189,923 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.66 on Friday. The firm has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $1.84. The stock has a market capitalization of $177.97 million, a PE ratio of -1.54 and a beta of 2.38. Caribou Biosciences, Inc. has a 12-month low of $1.38 and a 12-month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.08. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. On average, analysts forecast that Caribou Biosciences, Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. HC Wainwright boosted their price target on Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Bank of America decreased their price target on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Caribou Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.